Development of a Questionnaire on Patients' Perception of Their Oncology Care Pathway (Onco-PREMs) (OncoPREMs)

Development of a Questionnaire on Patients' Perception of Their Oncology Care Pathway

Healthcare systems are evolving, giving increasing prominence to the patient-centered model, accompanied by objective and perceived outcomes.

PREMs (Patient Reported Experience Measures) are used to assess how patients feel about their experience of care. PREMs enable patients to take an active role in their own care, and enable healthcare establishments to identify areas for improvement that can be incorporated into their quality processes.

In oncology, the collection of patient-perceived quality regarding their care pathway would enable better coordination of their care. While a few initiatives have emerged in the field of PREMs, the development of a reliable questionnaire assessing patient perception of their care pathway in oncology remains a challenge.

Study Overview

• Status: Not yet recruiting
• Conditions: Cancer
• Intervention / Treatment: Other: Data collection

Detailed Description

The aims of the study are to constitute a questionnaire to assess patients' perceptions of their oncology care pathway and to perform its psychometric validation.

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: Barbe Coralie, DR; Phone Number: +33 0326918822; Email: coralie.barbe1@univ-reims.fr
• Study Contact Backup: Name: Gestonnairedu CURRS, Dr; Phone Number: +33 0326918822; Email: currs@univ-reims.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patient with cancer regardless of location or stage.

Description

Inclusion Criteria:

• cancer patient
• regardless of location or stage
• Fluent in French
• aged more than 18 years old
• Agreeing to take part in the study

Exclusion Criteria:

• With an estimated life expectancy of less than 3 months
• In remission, untreated or without follow-up for more than 12 months
• Protected by law

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Cancer patient; Patient with cancer regardless of location or stage.	Other: Data collection; data collection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Psychometric validation	Stastistical analysis to confirm the psychometric validation of the IGQ questionnaire	Day 0

Collaborators and Investigators

• Sponsor: Institut Jean-Godinot
• Collaborators: Université de Reims Champagne-Ardenne
• Investigators: Principal Investigator: DIOURI Loubna, Institut Godinot

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2024
• Primary Completion (Estimated): November 1, 2025
• Study Completion (Estimated): November 1, 2025

Study Registration Dates

• First Submitted: April 4, 2024
• First Submitted That Met QC Criteria: April 4, 2024
• First Posted (Actual): April 10, 2024

Study Record Updates

• Last Update Posted (Actual): April 10, 2024
• Last Update Submitted That Met QC Criteria: April 4, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Oncology; questionnaire; psychometric validation; oncology care pathway; patients' perception
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: 2023_RIPH_005_OncoPREMs

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No